Evaxion Biotech A/S (NASDAQ:EVAX – Get Free Report) and Cardiol Therapeutics (NASDAQ:CRDL – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.
Profitability
This table compares Evaxion Biotech A/S and Cardiol Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Evaxion Biotech A/S | -347.83% | N/A | -79.40% |
| Cardiol Therapeutics | N/A | -118.65% | -85.28% |
Insider & Institutional Ownership
11.0% of Evaxion Biotech A/S shares are owned by institutional investors. Comparatively, 12.5% of Cardiol Therapeutics shares are owned by institutional investors. 41.6% of Evaxion Biotech A/S shares are owned by insiders. Comparatively, 5.3% of Cardiol Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Evaxion Biotech A/S | $70,000.00 | 204.87 | -$22.12 million | ($0.29) | -8.86 |
| Cardiol Therapeutics | $60,000.00 | 2,570.12 | -$20.84 million | ($0.33) | -5.85 |
Cardiol Therapeutics has lower revenue, but higher earnings than Evaxion Biotech A/S. Evaxion Biotech A/S is trading at a lower price-to-earnings ratio than Cardiol Therapeutics, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Evaxion Biotech A/S has a beta of -0.24, meaning that its share price is 124% less volatile than the S&P 500. Comparatively, Cardiol Therapeutics has a beta of 0.91, meaning that its share price is 9% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current ratings for Evaxion Biotech A/S and Cardiol Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Evaxion Biotech A/S | 0 | 0 | 2 | 0 | 3.00 |
| Cardiol Therapeutics | 0 | 0 | 4 | 1 | 3.20 |
Evaxion Biotech A/S presently has a consensus price target of $11.00, suggesting a potential upside of 328.02%. Cardiol Therapeutics has a consensus price target of $8.75, suggesting a potential upside of 353.37%. Given Cardiol Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Cardiol Therapeutics is more favorable than Evaxion Biotech A/S.
Summary
Cardiol Therapeutics beats Evaxion Biotech A/S on 10 of the 15 factors compared between the two stocks.
About Evaxion Biotech A/S
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.
About Cardiol Therapeutics
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.
Receive News & Ratings for Evaxion Biotech A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evaxion Biotech A/S and related companies with MarketBeat.com's FREE daily email newsletter.
